This episode of the Journal of Gynecologic Oncology podcast explores a study by Berthet and colleagues on the role of platinum-free interval in predicting the benefit of second-line chemotherapy in recurrent uterine and ovarian carcinosarcoma. Analyzing a retrospective cohort of 40 patients, the study found that patients with a progression-free survival of more than nine months had a significantly longer overall survival after relapse when treated with platinum- or anthracycline-based chemotherapy. In contrast, those with earlier recurrence derived little benefit from additional chemotherapy, with outcomes comparable to patients receiving only best supportive care. These findings suggest that platinum-free interval could serve as a useful marker to guide treatment decisions. Tune in for a discussion on the clinical implications, potential therapeutic targets, and the future of individualized treatment strategies in gynecologic carcinosarcoma.

Platinum free interval and clinical benefit of the second-line chemotherapy in recurrent uterine and ovarian carcinosarcoma: a retrospective cohort analysis.